Caris Life Sciences
750 West John Carpenter Freeway
Suite 800
Irving
Texas
75039
United States
Website: http://www.carislifesciences.com/
280 articles about Caris Life Sciences
-
Powered by Its Industry-Leading Comprehensive Multi-Omic Database, Caris Life Sciences to Showcase Extensive Research at ASCO 2023
5/23/2023
Caris Life Sciences® announced that the company and collaborators within the Caris Precision Oncology Alliance™ will collectively present 42 studies across more than 30 solid tumor types at the 2023 American Society of Clinical Oncology Annual Meeting from June 2-6, 2023.
-
The Caris Precision Oncology Alliance Welcomes Robert H. Lurie Comprehensive Cancer Center of Northwestern University
5/16/2023
Caris Life Sciences® announced that Robert H. Lurie Comprehensive Cancer Center of Northwestern University has joined the Caris Precision Oncology Alliance™.
-
The Caris Precision Oncology Alliance Welcomes Yale Cancer Center
5/9/2023
Caris Life Sciences®, the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced that Yale Cancer Center has joined the Caris Precision Oncology Alliance™.
-
The Caris Precision Oncology Alliance Welcomes the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
5/3/2023
Caris Life Sciences®, the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced that the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center has joined the Caris Precision Oncology Alliance™.
-
The Caris Precision Oncology Alliance Welcomes CARTI Cancer Center
4/27/2023
Caris Life Sciences®, the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced that CARTI Cancer Center has joined the Caris Precision Oncology Alliance™.
-
Caris Life Sciences to Showcase Research Highlighting the Clinical Value of Comprehensive Molecular Profiling at the American Association for Cancer Research Annual Meeting
4/14/2023
Caris Life Sciences® announced that the company and partners within the Caris Precision Oncology Alliance™ will collectively present four studies across 14 tumor types at the 2023 American Association for Cancer Research Annual Meeting being held April 14-19, 2023 in Orlando, Florida, at Booth Number 130.
-
The Caris Precision Oncology Alliance Welcomes University of Chicago Medicine Comprehensive Cancer Center
3/8/2023
Caris Life Sciences announced today that the University of Chicago (UChicago) Medicine Comprehensive Cancer Center has joined the Caris Precision Oncology Alliance™ (POA).
-
Caris Life Sciences and Incyte Enter Into Broad Precision Medicine Partnership to Advance Incyte's Oncology Pipeline
3/7/2023
Caris Life Sciences today announced a strategic research partnership with Incyte Corporation (NASDAQ:INCY) to augment precision medicine approaches for Incyte's oncology pipeline.
-
Caris Life Sciences to Showcase Research with Leading Cancer Centers at ASCO Genitourinary Cancers Symposium 2023 Reflecting Its Commitment to Improving Outcomes for Patients
2/13/2023
Caris Life Sciences® announced that the company and partners within the Caris Precision Oncology Alliance™ will collectively present five studies across three tumor types at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium, February 16-18, 2023 in San Francisco.
-
The Caris Precision Oncology Alliance Welcomes The UCI Health Chao Family Comprehensive Cancer Center
1/31/2023
The UCI Health Chao Family Comprehensive Cancer Center joins Caris' extensive network of leading cancer institutions committed to utilizing clinical data to advance patient care and outcomes.
-
Caris Life Sciences Raises $400 Million in Senior Secured Debt
1/19/2023
Caris Life Sciences®, the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced that the company has closed a senior secured term loan providing up to $400 million in capital from OrbiMed and Braidwell.
-
Caris Life Sciences to Showcase Extensive Research with Leading Cancer Centers at ASCO Gastrointestinal Cancers Symposium 2023 Reflecting Its Commitment to Improving Outcomes for Patients
1/17/2023
Caris Life Sciences® announced that the company and partners within the Caris Precision Oncology Alliance™ will collectively present 18 studies across more than six tumor types at the 2023 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, January 19-21, 2023 in San Francisco.
-
Caris Life Sciences and ConcertAI Form Broad Partnership Creating Industry-Leading Molecular Oncology Research Platform to Accelerate Drug Development and Novel Research
1/9/2023
Caris Life Sciences® and ConcertAI announced a unique partnership to align the two companies' oncology capabilities.
-
Elevation Oncology Announces Pipeline Prioritization, Realignment of Resources to Advance EO-3021 and CEO Transition
1/6/2023
Elevation Oncology, Inc. today announced plans to prioritize key research and development efforts to advance EO-3021, its potential best-in-class antibody-drug conjugate (ADC) designed to target Claudin18.2, and other pipeline programs including those through its existing partnership with Caris Life Sciences.
-
Caris Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
1/4/2023
Caris Life Sciences announced today that the company will present at the 41st Annual J.P. Morgan Healthcare Conference, which is being held January 9-12, 2023.
-
Caris Life Sciences to Present at the 2022 San Antonio Breast Cancer Symposium
12/7/2022
Caris Life Sciences announced today that it will present findings at the San Antonio Breast Cancer Symposium (SABCS) that illustrate the potential impact of molecular profiling on the treatment of breast cancer. SABCS is being held December 6-10, 2022 in San Antonio, Texas.
-
Caris Life Sciences and Hummingbird Bioscience Enter Into Collaboration to Advance Clinical Development of Anti-HER3 Therapy
12/6/2022
Caris Life Sciences and Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced a strategic collaboration to advance clinical development of Hummingbird Bioscience's anti-HER3 therapy, HMBD-001.
-
Caris' Precision Oncology Alliance Welcomes Cleveland Clinic Cancer Center
11/29/2022
Caris Life Sciences®, the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced that Cleveland Clinic Cancer Center has joined Caris' Precision Oncology Alliance™.
-
Caris' Precision Oncology Alliance Welcomes VCU Massey Cancer Center
10/25/2022
Caris Life Sciences® announced that Virginia Commonwealth University Massey Cancer Center has joined Caris' Precision Oncology Alliance™.
-
With the appointment of new CEOs, CMOs and CSOs, biopharma and life sciences organizations shuffled their leadership positions as Q3 comes to a close.